Verrica Pharmaceuticals Files 8-K on Financials
Ticker: VRCA · Form: 8-K · Filed: May 13, 2025 · CIK: 1660334
| Field | Detail |
|---|---|
| Company | Verrica Pharmaceuticals Inc. (VRCA) |
| Form Type | 8-K |
| Filed Date | May 13, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Verrica Pharma dropped an 8-K on financials, check it out.
AI Summary
Verrica Pharmaceuticals Inc. filed an 8-K on May 13, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, but does not specify any new material events or transactions.
Why It Matters
This filing provides an update on Verrica Pharmaceuticals' financial status and operational results, which is important for investors to assess the company's performance and outlook.
Risk Assessment
Risk Level: low — The filing is a routine update on financial condition and does not appear to disclose any new material risks or adverse events.
Key Players & Entities
- Verrica Pharmaceuticals Inc. (company) — Registrant
- May 13, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 484-453-3300 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Verrica Pharmaceuticals Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was this 8-K filing submitted?
This 8-K filing was submitted on May 13, 2025.
What is Verrica Pharmaceuticals Inc.'s state of incorporation?
Verrica Pharmaceuticals Inc. is incorporated in Delaware.
What is the principal executive office address for Verrica Pharmaceuticals Inc.?
The principal executive office address is 44 W. Gay St., Suite 400, West Chester, PA 19380.
Does this filing indicate any specific new material events or transactions?
This filing indicates it is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting on results of operations and financial condition, and includes financial statements and exhibits, but does not specify any new material events or transactions beyond these categories.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 13, 2025 regarding Verrica Pharmaceuticals Inc. (VRCA).